Project Grant R01CA281043

Award Date 6/1/24
Completion Date 5/31/29
Dollars Obligated $1.8M
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This $300,000 Project Grant awarded by the National Science Foundation (NSF) under the Integrative Activities (CFDA 47.083) program supports the development of an innovative, intelligent surgical probe for prostate cancer treatment. The project aims to create an edge artificial intelligence (AI) system-on-chip for bioimpedance analysis that can accurately distinguish cancerous from healthy tissue during prostate removal surgery. The novel technology being developed includes an adaptive filter to...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $598,046 to Case Western Reserve University (CWRU) to develop a rapid and reproducible magnetic resonance fingerprinting (MRF) method. The goal is to quantitatively and accurately characterize prostatic peripheral zone tissue to limit overdiagnosis and overtreatment of prostate cancer patients without clinically significant disease. The key products...
This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of an artificial intelligence-based system for analyzing multiparametric magnetic resonance imaging (MRI) scans to detect prostate lesions. The awardee, Taurus Diagnostics, Inc., will create a novel prostate cancer diagnostic platform leveraging artificial intelligence image analysis for high sensitivity and specificity. Key objectives include developing methods to...
This Project Grant award for $161,000.00, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a novel surgical probe prototype designed for Positron Emission Tomography (PET) radiotracers. The primary objective is to create a compact, lightweight probe suitable for use in laparoscopic prostate cancer resection procedures, which...
The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) provides $709,358 to develop an artificial intelligence (AI) surgical coaching system to enhance performance and outcomes in urologic endoscopy procedures. The project aims to create predictive machine learning models by analyzing video data and neuroergonomic metrics captured...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286), provides $1,751,591.00 to Case Western Reserve University (CWRU) to develop a theranostic agent called PSMA-1-PC413. This agent is designed for fluorescence-guided surgery and photodynamic therapy (PDT) to improve the treatment of prostate cancer. The key...
This $704,563 Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Beckman Research Institute of the City of Hope, aims to develop a quantitative MRI (qMRI) toolset and automated prostate cancer tumor segmentation method to improve identification of clinically significant prostate tumors for radiation therapy. The project involves three key objectives: 1) building a qMRI toolset using techniques like magnetic resonance...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is funding research to develop advanced AI-assisted prostate MRI interpretation capabilities. The $245,087 award to the University of Delaware will be used to: Curate a comprehensive dataset of 300 public and 50 Memorial Sloan Kettering (MSK) prostate MRI scans with corresponding PIRADS radiology reports. The University of Delaware team will leverage natural...
This $538,553 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a longitudinal study to investigate the use of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The University of Miami will lead this research, which aims to develop a multivariable model that...

HARNESSING LOW-FIELD MRI AND ROBOTICS TO ENABLE PERSONALIZED INCISIONLESS PROSTATE SURGERY - PROJECT SUMMARY/ABSTRACT OBJECTIVE: THE OVERARCHING GOAL OF OUR RESEARCH IS TO REPLACE INVASIVE RADICAL PROSTATECTOMY WITH TARGETED, MINI- MALLY INVASIVE IMAGE-GUIDED FOCAL RESECTION OF PROSTATE CANCER. WE PROPOSE TO ACCOMPLISH THIS BY COMBINING NOVEL LOW-FIELD MRI TECHNIQUES WITH A NEW KIND OF SURGICAL ROBOT CAPABLE OF DELIVERING TWO NEEDLE-SIZED MANIPULATORS INTO THE PROSTATE THROUGH A STANDARD TRANSURETHRAL ENDOSCOPE. SIGNIFICANCE: 1 IN 8 MEN WILL BE DIAGNOSED WITH PROSTATE CANCER IN THEIR LIFETIME, AND IT IS SECOND ONLY TO LUNG CANCER IN THE NUMBER OF MEN IT KILLS EVERY YEAR IN THE USA. THE GOLD STANDARD TREATMENT, RADICAL PROSTATECTOMY, INVOLVES COMPLICATIONS INCLUDING ALL THOSE OF MAJOR SURGERY, AS WELL AS HIGH RATES OF IMPOTENCE AND INCONTINENCE. RECENTLY, PIONEERING SURGEONS HAVE NOTED THE PROMISE OF PATIENT-SPECIFIC TRANSURETHRAL FOCAL RESECTION TO REDUCE COMPLICATION RATES. HOWEVER THE APPROACH IS CURRENTLY FUNDAMENTALLY LIMITED BY THE FACT THAT CANCEROUS TISSUE CANNOT BE VISUALLY DIFFERENTIATED FROM HEALTHY TISSUE IN ENDOSCOPE IMAGES, FORCING THE SURGEON TO "GUESS" WHERE THE CANCER IS, BASED ON MEMORY OF PREOPERATIVE MRI IMAGES. ULTRASOUND-MRI FUSION CANNOT IMPROVE THINGS, SINCE THE ULTRASOUND PROBE COMPRESSES THE PROSTATE, WHICH COLLAPSES THE URETHRA AND PRECLUDES TRANSURETHRAL INTERVENTIONS. WE PROPOSE TO ELIMINATE THE GUESSWORK AND ENABLE ACCURATE, PRECISE, PERSONALIZED FOCAL RESECTIONS BY FUSING HIGH-RESOLUTION PREOPERATIVE MRI WITH INTRAOPERATIVE LOW-FIELD MRI AND A NOVEL ROBOTIC SYSTEM. INNOVATION: THE CENTRAL INNOVATION OF THIS PROJECT IS TO ENABLE USE OF THE EMERGING GENERATION OF INEXPENSIVE, PORTABLE, AND OPEN LOW-FIELD MRI SCANNERS TO GUIDE FOCAL PROSTATE RESECTION. ADDITIONAL INNOVATION COMES FROM THE ROBOTIC SYSTEM WHICH WILL ENABLE PRECISE AND ACCURATE USE OF IMAGING INFORMATION. THE ROBOT WILL BE THE FIRST MRI-CONDITIONAL ROBOT ABLE TO DELIVER MULTIPLE MANIPULATORS THROUGH AN ENDOSCOPE. IT WILL FEATURE NEEDLE- SIZED, TENTACLE-LIKE MANIPULATORS AND DEPLOY THEM INTO THE PROSTATE THROUGH A STANDARD-DIAMETER TRANSURETHRAL ENDOSCOPE, FOR PRECISE RESECTION AND RETRACTION OF TISSUE. THIS WILL MAKE THE FOCAL RESECTION PROCESS MUCH EASIER AND MORE ACCURATE FOR THE SURGEON TO ACCOMPLISH. APPROACH: WE WILL CREATE OUR MRI-GUIDED ROBOTIC SYSTEM THROUGH THREE SPECIFIC AIMS. AIM 1 ACHIEVES FAST IN- TRAOPERATIVE IMAGING TO UPDATE THE SURGEON'S IMAGE GUIDANCE DISPLAY AS THEY REMOVE TISSUE. IN AIM 2 WE BUILD A NOVEL MRI-CONDITIONAL ROBOT AND INTEGRATE IT WITH THE LOW-FIELD MRI SCANNER. IN AIM 3 WE VALIDATE THE INTEGRATED SYSTEM IN ANTHROPOMORPHIC PHANTOMS WITH UROLOGIC SURGEONS. NOTE THAT CLINICAL TRANSLATION OF OUR SYSTEM WILL BE RAPID AT THE SUCCESSFUL CONCLUSION OF THIS R01. THIS PROJECT INCLUDES TWO INDUSTRY PARTNERS, PROMAXO, INC. WHICH HAS RECENTLY RELEASED AN FDA-APPROVED LOW-FIELD PROSTATE MRI SCANNER, AND VIRTUOSO SURGICAL, INC. WHICH IS DE- VELOPING A (NON-MRI-CONDITIONAL) TRANSURETHRAL ROBOT SLATED TO BE ON THE MARKET BY THE TIME THIS R01 CONCLUDES. THUS, SUCCESSFUL COMPLETION OF THIS R01 WILL PAVE THE WAY FOR COMMERCIAL TRANSLATION AND CLINICAL TRIALS, ENABLING US TO RAPIDLY BRING THE BENEFITS OF THIS RESEARCH TO DOCTORS AND THEIR PATIENTS.

Posted 5/13/24, 12:00 AM